I-Mab to Showcase Innovations at September Investor Conferences

Author: Owen Jenkins Updated: 08-21-2025 07:19 AM

Exciting Investor Conferences Ahead for I-Mab

ROCKVILLE, Md. — I-Mab (NASDAQ: IMAB), a distinguished global biotech firm, is preparing to engage with investors at significant conferences in September. This opportunity highlights its commitment to advancing precision immuno-oncology therapies for cancer treatment.

Upcoming Conference Details

I-Mab's management team is set to participate in two notable investor conferences:

Cantor Global Healthcare Conference

The company will hold one-on-one meetings during the Cantor Global Healthcare Conference, scheduled from September 3 to September 5. This format offers a valuable platform for personalized discussions about I-Mab's ongoing projects and strategies.

H.C. Wainwright 27th Annual Global Investment Conference

Following this, I-Mab will present at the H.C. Wainwright Conference on September 10, where they will provide insights into their innovative pipeline and business developments. The presentation will start at 9:30 AM ET. Investors interested in attending can find the webcast available on I-Mab’s News & Events page for up to 90 days post-event. This enriching platform will enable attendees to learn about I-Mab's latest advancements.

About I-Mab and Its Mission

I-Mab is on the cutting edge of biotechnology, spearheading the development of innovative immuno-oncology agents designed specifically for cancer treatment. Their current pipeline is particularly focused on *givastomig*, a bispecific antibody aimed at treating Claudin 18.2-positive gastric cancers. With promising results from Phase 1 trials, givastomig has demonstrated robust tumor-binding capabilities and anti-tumor activity, underpinned by its activation of T cells through the 4-1BB signaling pathway. This specialization offers hope not only for gastric cancers but potentially for a broader range of solid tumors.

Reaching Out to Investors

I-Mab values transparency and maintains open lines of communication with its investors and the broader community. Investors can find additional details about the company’s developments and strategies on their official website, ensuring they are well-informed about the latest advancements in the field of biotechnology.

Investor and Media Contacts

For further inquiries, I-Mab encourages direct engagement with their investor relations team:

PJ Kelleher

LifeSci Advisors

Phone: +1-617-430-7579

Email: pkelleher@lifesciadvisors.com

Email: IR@imabbio.com

Frequently Asked Questions

What are the key conferences I-Mab will participate in September?

I-Mab will participate in the Cantor Global Healthcare Conference and the H.C. Wainwright Annual Global Investment Conference.

When will I-Mab's presentation take place?

The presentation at the H.C. Wainwright Conference is scheduled for September 10 at 9:30 AM ET.

What is the purpose of these investor conferences?

These conferences provide I-Mab an opportunity to engage with investors, share insights about their innovative projects, and discuss their vision and pipeline.

What is givastomig?

Givastomig is I-Mab’s leading bispecific antibody designed for targeting Claudin 18.2-positive gastric cancers, showcasing strong anti-tumor activity as demonstrated in Phase 1 trials.

How can investors access the webcast of I-Mab’s presentation?

The webcast will be available on I-Mab's News & Events webpage for 90 days following the presentation.

About The Author

Hi there I'm 38-year-old author and financial consultant Owen Jenkins. Having worked in the financial sector for more than ten years, I am well-versed in the subtleties and complexity that mold our financial environment. Following a degree in finance, I worked in a number of financial institutions honing my abilities in market analysis, financial planning, and investment strategies.

My love is teaching others about investing and personal finance. My goal in writing many books and articles has been to demystify financial ideas and give readers the information they need to make wise financial decisions. I write with a direct, useful style that emphasizes doable suggestions for daily living.

Along with writing, I lead webinars and seminars where I impart knowledge on how to successfully negotiate the financial world. I also write for financial journals and show up as a guest expert on financial news programs a lot. Whether they are new to investing or want to improve their approach, my mission is to enable people to take charge of their financial futures.

Beyond work, I like to hike, play the guitar, and spend time with my family. I think that balance is crucial and want to encourage people to strike a balance between their financial aspirations and their hobbies. I want to help people succeed and achieve financial security through my work, so having a good influence.

Contact Owen Jenkins privately here. Or send an email with ATTN: Owen Jenkins as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.